5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione

• ChemBase编号: 1025
• 分子式: C12H18N2O2S
• 平均质量: 254.34852
• 单一同位素质量: 254.10889883
• SMILES: S=C1NC(=O)C(C(CCC)C)(CC=C)C(=O)N1
• Canonical SMILES: CCCC(C1(CC=C)C(=O)NC(=S)NC1=O)C
• InChI: InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
• InChIKey: XLOMZPUITCYLMJ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
• IUPAC传统名: thioseconal; thiamylal
• 商标名: Surital; Thioseconal
• 别名: 5-烯丙基-5-(1-甲基丁基)-2-硫代巴比妥酸; 硫戊巴比妥; Thiamylal; Thiamylal; Thiamylal; Thioseconal; Surital; Dihydro-5-(1-methylbutyl)-5-(2-propen-1-yl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; Bio-Tal; NSC 120815

登记号

• CAS号: 77-27-0
• EC号: 201-018-3
• MDL号: MFCD00057565
• PubChem SID: 160964488; 24900605; 46506261
• PubChem CID: 3032285
• CHEBI ID: 9536
• ATC码: QN01AF90
• CHEMBL: 440
• Chemspider ID: 2297298
• DrugBank ID: DB01154
• KEGG ID: D06106
• 美国药典/FDA物质标识码: 01T23W89FR
• 维基百科标题: Thiamylal

理论计算性质

JChem

• Acid pKa: 7.1973195
• 质子受体: 2
• 质子供体: 2
• LogD (pH = 5.5): 2.9151683
• LogD (pH = 7.4): 2.517312
• Log P: 2.9237015
• 摩尔折射率: 70.6389 cm^3
• 极化性: 27.72023 Å^3
• 极化表面积: 58.2 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.11
• LOG S: -3.7
• 溶解度: 5.06e-02 g/l

分子性质

理化性质

• 溶解度: 49.4 mg/L
• 疏水性(logP): 2.5

安全信息

• 欧盟危险性物质标志: 有毒(Toxic) (T)
• 联合国危险货物编号: 2811
• 德国WGK号: 3
• 联合国危险货物等级: 6.1
• 联合国危险货物包装类别(PG): 3
• 危险公开号: 23/24/25
• 安全公开号: 36/37/39-45
• GHS危险品标识: GHS06
• GHS警示词: Danger
• GHS危险声明: H301-H311-H331
• GHS警示性声明: P261-P280-P301 + P310-P311
• 个人保护装置: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 3
• 毒品管制信息: USDEA Schedule III; regulated under CDSA - not available from Sigma-Aldrich Canada

药理学性质

• 法定药品分级: Schedule III (Canada); Schedule III (US)

产品相关信息

• 级别: analytical standard

详细说明

DrugBank - DB01154

• Drug Groups: approved
• Description: A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
• Indication: Used for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.
• Pharmacology: Thiamylal, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
• Toxicity: Intravenous LD50 in rat is 51 mg/kg.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Absorption: Rapidly absorbed (high lipid solubility).
• Half Life: Although no studies have been performed on humans, the half-life in cats is 14.3 hours.
• External Links: Wikipedia

Sigma Aldrich - T9799

Biochem/physiol Actions
静脉内麻醉药

Toronto Research Chemicals - T344165

Thiamylal is a barbiturate derivative with sedative, anticonvulsant and hypnotic effects. Thiamylal is used for induction in surgical anaesthesia as well as an anticonvulsant to counteract side effects from other anaesthetics. Thiamylal is a Controlled Su

参考文献

• Hsieh, M.Y. et al.: Acta, Paediat. Tai., 46, 294 (2005)
• Lin C.K. et al.: Kaoh. J. Med. Sci., 26, 192 (2005)
• Tanaka, E. et al.: Neuriosci. Res., 64, 391 (2005)